Article
作者: Brianti, Pina ; Dini, Valentina ; Travaglini, Massimo ; Malagoli, Piergiorgio ; Caudullo, Francesco ; Gaiani, Francesca M. ; Bardazzi, Federico ; Gisondi, Paolo ; Burlando, Martina ; Brunasso, Giovanna ; Orsini, Diego ; Carrera, Carlo G. ; Licata, Gaetano ; Caproni, Marzia ; Balato, Anna ; Guarneri, Claudio ; Mercuri, Santo R. ; Lasagni, Claudia ; Cagni, Anna E. ; Narcisi, Alessandra ; Venturini, Marina ; Cuccia, Aldo ; Megna, Matteo ; Satolli, Francesca ; Musumeci, Maria L. ; Ruffo Di Calabria, Valentina ; Cascio Ingurgio, Ruggero ; Trovato, Emanuele ; Costanzo, Antonio ; Strippoli, Davide ; Loconsole, Francesco ; Dapavo, Paolo ; Gargiulo, Luigi ; Zichichi, Leonardo ; Carugno, Andrea ; Valenti, Mario ; Marzano, Angelo V. ; Ribero, Simone ; Di Brizzi, Eugenia V. ; Amoruso, Fabrizio ; Ibba, Luciano
PURPOSE:Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200 mg versus tildrakizumab 100 mg in patients with a high disease burden or high body weight.
MATERIALS AND METHODS:Our retrospective study included 134 patients treated with tildrakizumab 200 mg and 364 patients treated with tildrakizumab 100 mg from 28 Italian Dermatology Units affected by moderate-to-severe plaque psoriasis. The patients had a body weight above 90 kg or a high disease burden (Psoriasis Area and Severity Index [PASI] ≥ 16 or the involvement of difficult-to-treat areas). We evaluated the effectiveness of tildrakizumab at the week-16 visit in terms of PASI90, PASI100 and absolute PASI ≤ 2.
RESULTS:After 16 weeks of treatment with tildrakizumab 200 mg, PASI90 was reached by 57.5% of patients and PASI100 by 39.6% of patients. At the same time point, 34.3% and 24.2% of patients treated with tildrakizumab 100 mg achieved PASI90 and PASI100, respectively.
CONCLUSIONS:Our data suggest that tildrakizumab 200 mg has better effectiveness than tildrakizumab 100 mg in patients with a body weight ≥ 90 kg and a high disease burden.